CPT code 82951 represents a three-point oral glucose tolerance test that measures blood glucose at a fasting baseline and at two additional timed intervals after an oral glucose challenge. This diagnostic laboratory procedure is nationally relevant because it is a standard clinical tool for evaluating glucose regulation and diagnosing impaired glucose tolerance and diabetes, impacting screening and disease management across outpatient and laboratory settings. Key national payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for the three-sample oral glucose tolerance test, typical sites of service where the test is performed, and the importance of standardized timing and specimen handling. The publication also summarizes billing and coverage considerations commonly relevant to national payers, outlines common billing modifiers provided in the input, and highlights areas where policy updates or local medical necessity rules can affect coverage and reimbursement. Where specific payer policy details, associated taxonomies, ICD-10 pairings, or related service-line data are not included in the input, the document notes that detailed payer-specific policy content is not available in the source material. This piece serves as a practical reference for clinicians, billing staff, and policy analysts seeking a national-level overview of CPT code 82951 and its role in diagnostic glucose testing.